



01-15-02
af/1642
IDS/#6
1/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **DEX-0196**

Inventors: **Salceda et al.**

Serial No.: **09/807,201**

Filing Date: **April 25, 2001**

Examiner: **Unknown**


Group Art Unit: **1642**

RECEIVED
JAN 18 2002
TECH CENTER 1600/2900

Title: **Method of Daignosing, Monitoring,
Staging, Imaging and Treating
Prostate Cancer**

I, **Nathan P. Letts**, Registration No. **36,581**, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date:


Nathan P. Letts, Registration No. 36,581

12/12/2001

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above



identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- () A copy of the of the PCT Search Report for @@ which corresponds to the subject US application @@ is included.
- () In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were




previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed , for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

- () Due to the large size of some references, only relevant portions have been submitted. The included portions are as follows: @@ (@@). Full text of abbreviated reference is available if requested.
- () Reference @@ is in a foreign language therefore a Geneseq Patent search report is attached to demonstrate relevance.
- () The relevance of the listed references in a foreign language is as stated in the specification at pages @@.
- () All listed references are in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-0434. This form is submitted in duplicate.

Respectfully submitted,



Nathan P. Letts
Registration No. 36,581

Date: 12/17/2001

DiaDexus, Inc.
343 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 246-6400